Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Treasury Shares: 2020-2024

Historic Treasury Shares for BridgeBio Pharma (BBIO) over the last 5 years, with Dec 2024 value amounting to $275.0 million.

  • BridgeBio Pharma's Treasury Shares rose 17.55% to $323.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.3 million, marking a year-over-year increase of 17.55%. This contributed to the annual value of $275.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Treasury Shares is $275.0 million, which was down 0.00% from $275.0 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Treasury Shares peaked at $6.2 million during FY2022, and registered a low of $2.4 million during FY2020.
  • Its 3-year average for Treasury Shares is $6.2 million, with a median of $6.2 million in 2024.
  • Data for BridgeBio Pharma's Treasury Shares shows a peak YoY surged of 266.67% (in 2021) over the last 5 years.
  • BridgeBio Pharma's Treasury Shares (Yearly) stood at $75.0 million in 2020, then skyrocketed by 266.67% to $275.0 million in 2021, then remained steady at $275.0 million in 2022, then remained steady at $275.0 million in 2023, then remained steady at $275.0 million in 2024.